Indiplon
Insomnia
Neurocrine BiosciencesSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Insomnia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eszopiclone University of California, Los Angeles | Phase 4 | A |
Cipralex University of California, Los Angeles | Phase 4 | BBB |
LEMBOREXANT YangPan | Phase 4 | BBB |
Suvorexant Mayo Clinic | Phase 4 | BBB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- University of California, San Diego | Phase 3 | BB |
View all 40 →
Same molecule, other indications
Indiplon is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →